Transcode Therapeutics, Inc.(RNAZ)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Transcode Therapeutics, Inc. (RNAZ) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RNAZ is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RNAZ by reported 13-F value include Yorkville Advisors Global, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. RNAZ trades on the Nasdaq exchange and files with the SEC under CIK 1829635. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNAZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Transcode Therapeutics, Inc. directly from SEC EDGAR.